PRIMARY MISSION

The primary mission of REPROGEN is to conduct scientific research into reproductive DNA cloning technology to bring about births through such technology in the interest of science and its relationship to the advancement of the human condition. Reproductive DNA cloning technology provides a new and vibrant reproductive choice, particularly for those who may well have exhausted other reproductive methods.

Bringing about births from the tissues of living individuals allows those who wish to procreate in this manner to have this reproductive choice available. All testing and procedures for REPROGEN will be conducted outside of the United States. No human cloning will be conducted in the United States.

SECONDARY MISSION

The secondary mission of REPROGEN is to develop and apply embryonic stem cell technologies for the treatment of various diseases (diabetes, cancer, hematological, articular and bowel diseases, degenerative diseases of nervous system, different kinds of injuries, diseases of connective tissue and immune system, including AIDS, chronic infections and sepsis) and conditions (premature aging, male and female climax, involution and asthenic syndromes cachexia, etc.)

TERTIARY MISSION

The tertiary mission of REPROGEN is to apply propriety technology on embryo cryopreservation. This technology will be applied in assisting women to have access to a reliable oocyte cryopreservation regimen. Similarly, REPROGEN is aiming in establishing oocyte banks with cryopreserved oocytes obtained from healthy women with known genetic characteristics to be used in oocyte donation programs worldwide.

REPROGEN is currently working with a number of extremely reputable companies internationally to develop and employ its technologies to all interested parties worldwide. REPROGEN through its strengths in the biotechnology arena will remain a strong competitor and a leader in its field.